Kisqali

Active Ingredient(s): Ribociclib
FDA Approved: * March 13, 2017
Pharm Company: * NOVARTIS PHARMS CORP
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Kisqali Overview

Ribociclib (previously LEE 011) is an inhibitor of cyclin D1/CDK4 and CDK6, and is being studied as a treatment for drug-resistant cancers.[1] It was developed by Novartis and Astex Pharmaceuticals.[2] It was approved by the US FDA in March 2017 for use in combination with an aromatase inhibitor to treat some metastatic breast cancers.[3] It will be marketed as Kisqali.[3] Contents 1 Mechanism 2 Clinical trials 3 See also 4 References Mechanism For more details on this topic, see ...

Read more Kisqali Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ribociclib

Recent Kisqali Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ribociclib
  • Tablet: 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kisqali: (3 results)

Sorted by National Drug Code
  • 0078-0860 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
  • 0078-0867 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
  • 0078-0874 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation

Other drugs which contain Ribociclib or a similar ingredient: (1 result)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 17 October 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.